drugset / Trial / NCT04152655
A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease
Phase 2/3
Withdrawn
Second Affiliated Hospital, School of Medicine, Zhejiang University
Beijing Hospital · collabBeijing Tiantan Hospital · collabGuizhou Medical University · collabHuashan Hospital · collabJiangsu Province Nanjing Brain Hospital · collabPeking Union Medical College Hospital · collabPeking University Shenzhen Hospital · collabQilu Hospital of Shandong University · collabSecond Affiliated Hospital of Soochow University · collabSir Run Run Shaw Hospital · collabThe Affiliated Hospital of Hangzhou Normal University · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of Dalian Medical University · collabThe First Affiliated Hospital of Guangzhou Medical University · collabTongji Hospital · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabWest China Hospital · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate whether 24 months of idebenone may reduce the progression from Prodromal Parkinson disease (PPD) to Parkinson disease (PD).
Timeline
- Start
- 2020-01-01
- Primary completion
- 2022-01-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Idebenone | Small molecule | 30 mg | Oral |